Ad
Search
Generic filters
Filter by content type
Taxonomy terms

VACC – Vaccitech PLC

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.6

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 18.75

Low: 16

High: 23

Total Analysts: 5

Company Profile

Vaccitech plc, formerly Vaccitech Ltd, is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses